Department of Human Genetics, Hannover Medical School, Hannover, Germany.
Genes Chromosomes Cancer. 2019 Mar;58(3):139-148. doi: 10.1002/gcc.22665. Epub 2019 Jan 7.
Chromosomal rearrangements involving one donor chromosome and two or more recipient chromosomes are called jumping translocations. To date only few cases of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with jumping translocations have been described and the underlying mechanisms remain unclear. Here, we analyzed 11 AML and 5 MDS cases with jumping translocations. The cases were analyzed by karyotyping, FISH, telomere length measurement, and next-generation sequencing with an AML/MDS gene panel. Cases with jumping translocations showed significantly (P < .01) shorter telomeres in comparison to healthy age-matched controls. Additional neo-telomeres were found in two cases. In total, eight cases showed recipient chromosomes with a breakpoint in the centromeric region all of them harboring a pathogenic variant in the TP53 gene (n = 6) and/or a loss of TP53 (n = 5). By contrast, no pathogenic variant or loss of TP53 was identified in the six cases showing recipient chromosomes with a breakpoint in the telomeric region. In conclusion, our results divide the cohort of AML and MDS cases with jumping translocations into two groups: the first group with a telomeric breakpoint of the recipient chromosome is characterized by short telomeres and a possibly telomere-based mechanism of chromosomal instability formation. The second group with a centromeric breakpoint of the recipient chromosome is defined by mutation and/or loss of TP53. We, therefore, assume that both critically short telomeres as well as pathogenic variants of TP53 influence jumping translocation formation.
涉及一条供体染色体和两条或更多受体染色体的染色体重排称为跳跃易位。迄今为止,只有少数急性髓系白血病 (AML) 和骨髓增生异常综合征 (MDS) 伴有跳跃易位的病例被描述,其潜在机制尚不清楚。在这里,我们分析了 11 例 AML 和 5 例 MDS 伴有跳跃易位的病例。通过核型分析、FISH、端粒长度测量和 AML/MDS 基因面板的下一代测序对病例进行分析。与健康年龄匹配的对照组相比,跳跃易位病例的端粒明显(P <.01)更短。在两个病例中发现了额外的新端粒。总共,8 例显示受体染色体的着丝粒区域有一个断点,其中所有这些都携带 TP53 基因的致病性变异(n = 6)和/或 TP53 缺失(n = 5)。相比之下,在 6 例显示受体染色体在端粒区域有断点的病例中,未发现致病性变异或 TP53 缺失。总之,我们的结果将 AML 和 MDS 伴有跳跃易位的病例分为两组:第一组受体染色体的端粒断点特征是端粒较短,并且可能存在基于端粒的染色体不稳定形成机制。第二组受体染色体的着丝粒断点由突变和/或 TP53 缺失定义。因此,我们假设短端粒以及 TP53 的致病性变异都影响跳跃易位的形成。